Advent of High-Throughput System aids in Expansion of United States Non-Invasive Prenatal Testing (NIPT) Market

Published Date : Apr 18, 2018

ALBANY, New York, April 18, 2018 - has announced the addition of a new report titled “United States Non-Invasive Prenatal Testing (NIPT) Market Analysis (Actual and Potential), By Pregnancy Risk Level (High & Average Risk), Major Deals, Reimbursement, Key Company Profiles & Demand Forecasts to 2018 - 2023” to its offering. The report on the United States (U.S.) non-invasive prenatal testing (NIPT) market presents an elaborate assessment of various growth factors, prominent regional trends shaping the current trajectory, recent deals and agreements, lucrative avenues, and the overall competitive landscape.

The study takes a critical look at the prevailing regulatory landscape, reimbursement system, and legal and ethical issues influencing the current and emerging dynamics of the United States NIPT market. The market is projected to rise at a prominent pace during the forecast period of 2018–2023 and is prognosticated to reach a worth of USD 2.5 Billion by 2023 end.

The rising demand for genetic tests that can non-invasively screen as well as detect trisomy 21 in pregnant women, especially to reduce the incidence of aneuploid children among older mothers, is a notable factor driving the market. The substantial demand for NIPT for detecting chromosome abnormality in a non-invasive way as against chorionic villus sampling (CVS) or amniocentesis is a significant factor driving the market. The need for invasive tests are only recommended that if NIPT undergone previously has shown positive result for trisomy in mothers. The lack of clinical feasibility of using invasive prenatal diagnosis for low-risk mothers is also favoring the demand for NIPT in the U.S.

For Sample Copy, click here:

The striking accuracy obtained in NIPT results is one of the most vital factors behind its popularity. The growing prevalence of chromosomal aneuploidies in high-risk pregnancies is bolstering the demand for NIPT in the U.S.  Non-invasive prenatal testing is also gaining wide traction among the regional population given the fact that its guides early reproductive decision making for couples. The advent of high-throughput system is expanding the avenue of the U.S. NIPT market.

Recent innovations are leading to the next-generation sequencing approaches and have helped players gather crucial data from analyzing mother’s blood. Relentless efforts made by clinicians to develop better processes bode well for the market. Advances made in bioinformatics algorithms will help in the further expansion. The growing peculiarity of targeted sequencing for screening bodes well for the market. Though NIPT is making huge stride in the advanced countries, its commercialization is still keenly awaited in the U.S.

A number of players are entering into strategic collaborations, mergers and acquisition, licensing and exclusive rights, and licensing deals, to gain a competitive edge others. They are also investing in bolstering their distribution networks, in a move to gain a firm foothold in the U.S. NIPT market. Some of the prominent players operating in the market include Ariosa Diagnostics (Roche), Sequenom Laboratories, Natera Inc., Illumina, Inc., and Sequenom.

To order report Call Toll Free: 866-997-4948 or send an email on